Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00936936 · ClinicalTrials.gov registry record · Phase 2
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
A Phase 2 study of Testicular Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 2
- Study locations
NCT00936936: Completed Phase 2 study of Testicular Cancer, sponsored by M.D. Anderson Cancer Center.
NCT00936936 is a Phase 2 study of Testicular Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 64 participants, below the 89-participant average among 11 other Testicular Cancer trials with a reported enrollment target (28% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00936936, a Phase 2 study of Testicular Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical research study is to learn if 2 cycles of high-dose chemotherapy can help to control germ-cell tumors. The first cycle of chemotherapy will include the drugs gemcitabine, docetaxel, melphalan, and carboplatin. The second cycle of chemotherapy will include the drugs ifosfamide, carboplatin, and etoposide. The safety of these drug combinations will also be studied. This is an investigational study. Gemcitabine, docetaxel, melphalan, ifosfamide, carboplatin, and etoposide are all FDA-approved and commercially available for the treatment of germ-cell tumors. Up to 67 patients will be enrolled in this study.
Primary Outcome
Event-free survival estimated from the first day of High-Dose Course Cycle #1 (Day -6) until tumor progression, relapse, or death from any cause.
Conditions Studied
Interventions
- DRUG Melphalan
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Mesna
- DRUG Gemcitabine
Study Locations (2)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2009-06-02 |
| Est. Completion | 2024-01-11 |
| Phase | Phase 2 |
What the finished NCT00936936 record still lists
NCT00936936 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 89-participant average among 11 other Testicular Cancer trials with a reported enrollment target (28% lower).
The record links to 1 condition, with Testicular Cancer appearing as the primary indexed condition, and to 5 interventions - of which Melphalan is the first listed.
NCT00936936 reports a single indexed study location in Texas, Washington.
Frequently Asked Questions
What is clinical trial NCT00936936 about?
NCT00936936 is a clinical study titled "High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors". The goal of this clinical research study is to learn if 2 cycles of high-dose chemotherapy can help to control germ-cell tumors. The first cycle of chemotherapy will include the drugs gemcitabine, docetaxel, melphalan, and carboplatin. The second cycle of chemotherapy will include the drugs ifosfami...
What is the current status of trial NCT00936936?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2009-06-02. Estimated completion is 2024-01-11.
What conditions does trial NCT00936936 study?
This clinical trial studies the following conditions: Testicular Cancer.
What interventions are being tested in trial NCT00936936?
The interventions under investigation include: Melphalan (DRUG), Carboplatin (DRUG), Docetaxel (DRUG), Mesna (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00936936?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00936936 being conducted?
This trial has 2 study locations across Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Testicular Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00936936's enrollment target sits among peer trials
64 7th of 11 higher than 5 of 11 other Testicular Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Testicular Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
RECRUITING · Phase 2
-
Patient Reported Experiences With Sparing External Oblique Fascia Vs Standard Inguinal Orchiectomy
RECRUITING · NA
-
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
RECRUITING · Phase 1
-
Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.
RECRUITING · Phase 3
-
A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors
RECRUITING · NA
-
A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI